DICE THERAPEUTICS, INC.
400 East Jamie Court, Suite 300
South San Francisco, California 94080
October 5, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: | Office of Life Sciences | |
Re: | DICE Therapeutics, Inc. Registration Statement on Form S-3 Filed October 3, 2022 File No. 333-267702 |
Via EDGAR - Acceleration Request
Requested Date: October 7, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
DICE Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Amanda L. Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
Sincerely, | ||
DICE THERAPEUTICS, INC. | ||
By: | /s/ Scott Robertson | |
Scott Robertson | ||
Chief Financial Officer |
cc: | J. Kevin Judice, Ph.D., Chief Executive Officer |
Scott Robertson, Chief Business Officer
and Chief Financial Officer
DICE Therapeutics, Inc.
Robert A. Freedman, Esq.
Amanda L. Rose, Esq.
Fenwick & West LLP